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Introduction
An understanding of the health and economic impact of
C. difficile infections (CDI) can inform investments in
prevention and treatment interventions.
Objectives
To estimate the burden of CDI in the US using a meta-
analysis and economic model.
Methods
We searched PubMed, CINAHL, EMBASE and others for
multicenter studies published in the US between 2000-
2014 that evaluated CDI outcomes or costs. Studies were
included in the economic analysis if they measured post-
infection costs, post-infection length of stay (LOS), or pro-
pensity score-matched CDI patients to non-CDI controls.
We also included studies that evaluated CDI-associated
mortality with a control group. We created an economic
model using TreeAgePro 2014.
Results
When the 22 studies that evaluated mortality were
pooled, CDI was associated with a 2.5-fold increase in
mortality compared with other hospitalized patients
(pooled RR=2.54; 95% CI: 1.89, 3.40). Only 4 low/mod-
erate quality studies evaluated costs of CDI. The mean
CDI-attributable cost of the index hospitalization ranged
from $8,426 to $48,500. The mean costs per CDI after
discharge were $1,592 for outpatient visits and $14,847
for readmissions. When these values were adjusted to
2013 US dollars and included in the economic model,
we found that the mean total cost of a CDI was $32,198
(SD =$9,798). Of the 3 studies that evaluated LOS using
propensity matching, the mean CDI-attributable LOS
was 12.3 days. When this excess LOS was multiplied by
an average cost per day from a private 3rd party payer
perspective, CDI cost an average of $56,663 (SD =
$19,804).
Conclusion
Pooled estimates from the currently available literature
suggest that CDI is associated with large health and eco-
nomic burdens. However, the majority of available studies
were of moderate/low quality and may overestimate the
outcomes. Thus, these estimates should be used with cau-
tion and higher-quality studies should be completed to
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